CD33 and neoplasm: We found that HMGB1, secreted from tumor cells treated with DOC-based chemotherapy, did not influence the presence of suppressive myeloid (CD33+/CD11b+ MDSC) or Foxp3+Treg cells in tumors (Additional file 1: Figure S8).